Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 4/20 | 0.36 |
| ▸ | CTSS | P25774 | 4/20 | 0.36 |
| ▸ | CTSK | P43235 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487260 | 0.92 | POLB (0.45) | POLBHSD17B10HPGDTSHRUSP2 | |
| SCHEMBL6486103 | 0.91 | POLB (0.44) | POLBHSD17B10HPGDTSHRUSP2 | |
| SCHEMBL6482889 | 0.90 | CTSL (0.47) | POLBHSD17B10HPGDCTSLCTSS | |
| SCHEMBL6485523 | 0.85 | POLB (0.39) | POLBHSD17B10HPGDTSHRUSP2 | |
| SCHEMBL6484912 | 0.85 | CTSL (0.52) | POLBHSD17B10HPGDTSHRUSP2 | |
| SCHEMBL6590445 | 0.84 | CTSK (0.32) | POLBHSD17B10CTSLCTSSCTSK | |
| SCHEMBL6482786 | 0.84 | POLB (0.41) | POLBHSD17B10HPGDTSHRUSP2 | |
| SCHEMBL6484547 | 0.84 | HPGD (0.44) | POLBHSD17B10HPGDTSHRUSP2 | |
| SCHEMBL6475894 | 0.82 | CTSK (0.49) | LMNACTSLCTSSCTSK | |
| SCHEMBL6486305 | 0.82 | CTSL (0.45) | POLBHSD17B10HPGDTSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | claimed |
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | POLB 3719/4885HSD17B10 1318/4885HPGD 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.